J&J in discussions to buy Ollin Biosciences for up to $3.4B - report
Johnson & Johnson might announce a potential acquisition of Texas-based biotech firm Ollin Biosciences on Monday for a maximum of $3.4 billion, according to the Financial Times. The deal would see J&J paying a substantial $2.2 billion in cash upfront, complemented by an additional $1.2 billion in potential milestone payments, according to individuals familiar with the negotiations.
Ollin Biosciences has been actively advancing its experimental drug OLN324 through late-stage trials, aiming to treat two prevalent eye diseases - diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These conditions significantly contribute to vision loss. In June, Ollin Biosciences secured $330 million in funding to further its development efforts.
At present, Reuters has been unable to independently verify the reported figures. Neither Johnson & Johnson nor Ollin Biosciences have responded to Reuters' inquiries for comment outside of regular business hours.
Earlier this year, Johnson & Johnson made a significant move by acquiring biotech Firefly Bio for $1 billion in cash, as the company sought to bolster its cancer drug portfolio. Additionally, in 2025, J&J acquired Intra-Cellular Therapies for $14.6 billion to strengthen its position in the market for neurological disorder treatments.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.